[go: up one dir, main page]

AR067903A1 - Metodo para tratar la depresion mediada por estres - Google Patents

Metodo para tratar la depresion mediada por estres

Info

Publication number
AR067903A1
AR067903A1 ARP080103495A ARP080103495A AR067903A1 AR 067903 A1 AR067903 A1 AR 067903A1 AR P080103495 A ARP080103495 A AR P080103495A AR P080103495 A ARP080103495 A AR P080103495A AR 067903 A1 AR067903 A1 AR 067903A1
Authority
AR
Argentina
Prior art keywords
patient
depression
gaboxadol
abnormal
levels
Prior art date
Application number
ARP080103495A
Other languages
English (en)
Original Assignee
Lundbeck & Co As H
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lundbeck & Co As H filed Critical Lundbeck & Co As H
Publication of AR067903A1 publication Critical patent/AR067903A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Rheumatology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

La presente se refiere a un método para el tratamiento de la depresion que comprende administrar una cantidad eficaz terapéutica de gaboxadol a un paciente, donde los niveles de uno o más marcadores inflamatorios en dicho paciente están aumentados o son anormales. Se refiere además a un método para el tratamiento de la depresion mediada por estrés que comprende administrar una cantidad eficaz para uso terapéutico de gaboxadol a un paciente, donde los niveles de uno o más marcadores inflamatorios en dicho paciente están aumentados o son anormales. Reivindicacion 11: El método de acuerdo con cualquiera de las reivindicaciones 1-10 donde al paciente se le administra adicionalmente una cantidad eficaz terapéutica de escitalopram o su sal aceptable para uso farmacéutico.
ARP080103495A 2007-08-13 2008-08-11 Metodo para tratar la depresion mediada por estres AR067903A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DKPA200701154 2007-08-13

Publications (1)

Publication Number Publication Date
AR067903A1 true AR067903A1 (es) 2009-10-28

Family

ID=39798236

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP080103495A AR067903A1 (es) 2007-08-13 2008-08-11 Metodo para tratar la depresion mediada por estres

Country Status (4)

Country Link
AR (1) AR067903A1 (es)
CL (1) CL2008002368A1 (es)
TW (1) TW200920358A (es)
WO (1) WO2009021521A2 (es)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL2007112C2 (en) * 2011-07-14 2013-01-15 Brainlabs B V Novel diagnostic method for diagnosing depression and monitoring therapy effectiveness.
CA3133249C (en) 2012-02-09 2023-07-25 Memed Diagnostics Ltd. Signatures and determinants for diagnosing infections and methods of use thereof
KR20170041907A (ko) 2014-08-14 2017-04-17 메메드 다이어그노스틱스 리미티드 매니폴드 및 초평면을 이용한 생물학적 데이터의 컴퓨터 분석법
US20170234873A1 (en) 2014-10-14 2017-08-17 Memed Diagnostics Ltd. Signatures and determinants for diagnosing infections in non-human subjects and methods of use thereof
CN111624345A (zh) 2014-12-11 2020-09-04 米密德诊断学有限公司 用于诊断多种感染的标记组合及其使用方法
KR20180031721A (ko) 2015-07-17 2018-03-28 오비드 테라퓨틱스 인크. 가복사돌로 발달장애들을 치료하는 방법들
WO2017149548A1 (en) 2016-03-03 2017-09-08 Memed Diagnostics Ltd. Rna determinants for distinguishing between bacterial and viral infections
IL294121B2 (en) 2016-03-03 2023-09-01 Memed Diagnostics Ltd An RNA test to diagnose the type of infection
CN109661578B (zh) 2016-07-10 2022-05-10 米密德诊断学有限公司 用于区分细菌和病毒感染的蛋白质特征
US11340223B2 (en) 2016-07-10 2022-05-24 Memed Diagnostics Ltd. Early diagnosis of infections
WO2018031748A1 (en) 2016-08-11 2018-02-15 Ovid Therapeutics Inc. Methods and compositions for treatment of epileptic disorders
US11385241B2 (en) 2016-09-29 2022-07-12 Memed Diagnostics Ltd. Methods of prognosis and treatment
CN110073220A (zh) 2016-09-29 2019-07-30 米密德诊断学有限公司 风险评估和疾病分类的方法
US10209260B2 (en) 2017-07-05 2019-02-19 Memed Diagnostics Ltd. Signatures and determinants for diagnosing infections and methods of use thereof
US10813918B2 (en) 2017-08-04 2020-10-27 Ovid Therapeutics Inc. Use of Gaboxadol in the treatment of diabetes and related conditions
AU2019384157A1 (en) 2018-11-21 2021-06-17 Certego Therapeutics Inc. Gaboxadol for reducing risk of suicide and rapid relief of depression
KR20210105387A (ko) 2018-12-17 2021-08-26 오비드 테라퓨틱스 인크. 비-24 시간 수면-각성 장애의 치료를 위한 가복사돌의 사용
WO2021127308A1 (en) 2019-12-18 2021-06-24 Ovid Therapeutics Inc. GABOXADOL FOR THERAPEUTIC TREATMENT OF 1p36 DELETION SYNDROME
WO2021236876A2 (en) 2020-05-20 2021-11-25 Certego Therapeutics Inc. Ring deuterated gaboxadol and its use for the treatment of psychiatric disorders
CN113730439A (zh) * 2021-09-09 2021-12-03 陕西中鸿瑞康健康管理有限公司 能降低甘油三酯的干细胞因子冻干粉及其制备方法和应用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1641456T3 (da) * 2003-06-25 2010-06-21 Lundbeck & Co As H Gaboxadol til behandling af depression og andre affektive lidelser
AU2004324938A1 (en) * 2004-06-29 2006-05-26 H. Lundbeck A/S Treatment of neuropathic pain, fibromyalgia or rheumatoid arthritis
US20070203216A1 (en) * 2006-02-14 2007-08-30 Bjarke Ebert Method of treating inflammatory diseases

Also Published As

Publication number Publication date
WO2009021521A3 (en) 2009-04-23
TW200920358A (en) 2009-05-16
CL2008002368A1 (es) 2009-01-02
WO2009021521A2 (en) 2009-02-19

Similar Documents

Publication Publication Date Title
AR067903A1 (es) Metodo para tratar la depresion mediada por estres
UY32989A (es) Coposiciones terapéuticas concentradas de fosfolípidos
AR044007A1 (es) Metodos para el tratamiento de la enfermedad de parkinson
EA200870254A1 (ru) Способ лечения воспалительных заболеваний
CR11510A (es) Uso de un inhibidor de la gamma-secretasa para tratamiento del cancer
CL2013000304A1 (es) Compuestos derivados de 2-arilamino-bencimidazoles inhibidores de prostaglandina e2 (mpges-1); composicion farmaceutica que los comprende; compuestos intermediarios; uso en el tratamiento de enfermedades inflamatorias y/o afecciones asociadas, en particular el dolor.
NI201000105A (es) Régimen de dosificación asociado con ésteres de paliperidona inyectables de acción prolongada.
AR101740A1 (es) Terapia de combinación y composiciones
BR112012004806B8 (pt) composições imunogênicas que incluem moduladores da atividade de tlr, método para aumento da eficácia da referida composição e uso
MX2010005931A (es) Profarmacos de tetrahidrocanabinol, composiciones que comprenden profarmacos de tetrahidrocanabinol y metodos para utilizar los mismos.
CO6531463A2 (es) Combinaciones de un inhibidor de pi3k y un inhibidor de mek
BRPI0919020A2 (pt) Uso de células de linhagem monocitária enriquecidas para tratar isquemia e para tratar angina pectoris
AR083395A1 (es) Derivado peptidico nmu (neuromedina u) con elevado efecto anorectico
AR062401A1 (es) Uso de derivados del 2,5-dihidroxibenceno para tratar dermatitis
UY30158A1 (es) Uso de derivados de benzo-heteroaril sulfamida para el tratamiento del dolor
AR093182A1 (es) Metodo para tratar el sobrepeso o la obesidad
GT200800307A (es) 18-metil-19-nor-androst-4-en-17,17-espiroeteres (18-metil-19-nor-20-espirox-4-en-3-onas), asi como preparaciones farmaceuticas que los contienen
ECSP13012551A (es) Terapia de combinación para tratar infección por hcv.
DOP2013000131A (es) Composiciones y métodos para tratar el cáncer usando un inhibidor de pi3k y un inhibidor de mek
EA200970127A1 (ru) Модулятор рецепторов глюкокортикостероидов и способы его применения
MX2008011454A (es) Uso novedoso de agentes antihistaminicos para el tratamiento preventivo o temprano de sindromes inflamatorios, en particular los que son accionados por togavirus.
AR079000A1 (es) Terapia anticancerosa dirigida a celulas madre cancerosas resistentes a las drogas
UY31143A1 (es) Derivados de [1,10]-fenantrolina para el tratamiento de enfermedades neurodegenerativas o hematologicas
UY30557A1 (es) Tratamiento y prevencion de la fibrosis intestinal
GT200700020A (es) Compuestos y derivados de dibencilamina

Legal Events

Date Code Title Description
FB Suspension of granting procedure